Prevention of edema in long flights with Pycnogenol®

The aim of this study was to evaluate the prevention of edema during long-haul flights with an oral, anti-edema and antithrombotic agent (Pycnogenol (R), Horphag, Research Management SA, Geneva, Switzerland) in asymptomatic subjects. The assessment of edema was performed by evaluating an analogue scale, the rate of ankle swelling by strain-gauge derived rate of ankle swelling (RAS), and by assessing the ankle circumference variation. The study included 211 subjects; 169 completed the study (88 in the control group and 81 in the Pycnogenol (R) group). There were no important differences between the two groups (comparable for age, gender, weight, body mass index, and pattern distribution). The edema score, the RAS, and the circumference at inclusion were also comparable. After the flight in those treated with Pycnogenol (R), the edema score was increased only by 17.9% (vs. an increase of 58.3% in the control group) (p < 0.05). The RAS, evaluated in 22 subjects in the Pycnogenol (R) group (age 44.5; SD 8) and in 23 in the control group (age 45; SD 9) was increased on average by 91% in the control group and 36% in the Pycnogenol (R) group (p < 0.05). The variation on circumference at the ankle was 6% in the Pycnogenol (R) group (11% in the control group; p < 0.05). These results indicate a positive effect of Pyenogenol (R) on edema during long flights when considering subjective and objective data. No unwanted effects were observed.